<DOC>
	<DOCNO>NCT01900782</DOCNO>
	<brief_summary>This withdrawn study assess safety efficacy secukinumab compare etanercept placebo patient moderate severe , chronic , plaque-type psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Study Subcutaneous Secukinumab Treatment Subjects With Moderate Severe Chronic Plaque-type Psoriasis Compared Etanercept Placebo .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Chronic plaquetype psoriasis , moderate severe Candidate systemic therapy define psoriasis adequately control : topical treatment , phototherapy and/or previous systemic therapy Forms psoriasis chronic plaquetype Ongoing use treatment allow psoriasis Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>